))
Changing the drug development treatment paradigm: Hilary Eaton on AI and LLMs
Manage episode 504051326 series 3079777
Content provided by pharmaphorum. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by pharmaphorum or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Hilary Eaton, a rare disease advocate and chief business officer at Profluent about AI-first protein design and its part in accelerating biomedicine.
Eaton discusses her advocacy, gene editing, and how real-world evidence shows that AI scaling laws – which predict model performance based on size and computing power – apply to biology.
You can also listen to episode 202a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
287 episodes
Share
